←
Incyte2,065 posts
Incyte avatar✓

Incyte ✓

@Incyte

Incyte’s official Twitter. Ready to Solve On. See our Community Guidelines: bit.ly/2sV0H5W

◷ Joined October 2015▧ 831 Photos and videos
Incyte avatar
Incyte@Incyte·Nov 16

Today, we announced that the European Commission has granted marketing authorization in the EU for a treatment for eligible adults with moderate to severe hidradenitis suppurativa (HS). Visit our website to learn more. bit.ly/4iIDRoB

0:10
Incyte avatar
Incyte@Incyte·Nov 4

We're excited to join the hematology community at #ASH26! Explore the data we'll be presenting and follow along for updates from the meeting. bit.ly/3WgK2aJ

Post attachment
Incyte avatar
Incyte@Incyte·Oct 29

Read our press release to learn about our Q3 financial results and business updates, including progress across our portfolio. bit.ly/3UTF7Mo

0:10
Incyte avatar
Incyte@Incyte·Oct 26

Learn more from Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development, on the progress being made across our GI oncology portfolio at #ESMO26. bit.ly/4yDiOs9

0:15
Incyte avatar
Incyte@Incyte·Oct 26

Incyte shared new data from our KRAS G12D and TGFβR2xPD-1 programs in PDAC and MSS CRC at #ESMO26. Learn more. bit.ly/3WMBt7v

0:10
Incyte avatar
Incyte@Incyte·Oct 24

Despite advances, pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat. Understanding KRAS G12D mutations is central to advancing more targeted research for these patients. Learn more. #SolveOn bit.ly/4iaUDfX

Post attachmentPost attachmentPost attachment
Incyte avatar
Incyte@Incyte·Oct 24

We’ve announced a clinical trial collaboration with @Genmab for patients with first-line metastatic colorectal cancer (CRC) harboring a KRAS G12D mutation. Learn more. bit.ly/4BpE07x

0:07
Incyte avatar
Incyte@Incyte·Oct 22

⏰ #ESMO26 begins tomorrow! We're looking forward to sharing new data from our solid tumor portfolio, including research in pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable colorectal cancer (MSS CRC). Read our press release to learn more. bit.ly/4siy248

Post attachment
Incyte avatar
Incyte@Incyte·Oct 7

From our booth to sessions at the #EADVCongress, it was exciting to connect with the global dermatology community and share the latest in inflammation and autoimmunity.

0:10
Incyte avatar
Incyte@Incyte·Sep 30

There’s more to vitiligo than what appears on the skin. A deeper understanding of the condition and the experiences of people living with it is essential to continued progress. Learn more about Incyte’s work to address patient needs through science and innovation. bit.ly/4AERnjV

0:10
Incyte avatar
Incyte@Incyte·Sep 29

At this year’s #EADVCongress we’ll join researchers, clinicians and advocates from around the world to discuss how a deeper understanding of immune-mediated skin conditions can help advance research and patient care. bit.ly/4xUWYA7

0:23
Incyte avatar
Incyte@Incyte·Sep 25

An important milestone for people living with fibrodysplasia ossificans progressiva (FOP). The @FDA has approved an oral ALK2 inhibitor developed by Incyte and licensed to @mirumpharma for worldwide development and commercialization. Learn more in the press release. bit.ly/4rxVfza

0:08
Incyte avatar
Incyte@Incyte·Sep 25

Here’s a look at where data from the Incyte portfolio will be throughout this year’s #EADVCongress. We look forward to connecting with the dermatology community and advancing important scientific conversations. bit.ly/4iJuS73

0:14
Incyte avatar
Incyte@Incyte·Sep 22

Join us at the upcoming European Academy of Dermatology and Venereology (EADV) Congress where we will share our latest scientific advancements in inflammation and autoimmunity. Learn more about our data. #EADVCongress bit.ly/4dtDsDk

0:17
Incyte avatar
Incyte@Incyte·Aug 10

We're attending the @nbd_foundation's 78th Annual Bleeding Disorders Conference (BDC) in Orlando, August 13–15. Our team is excited to listen to, learn from and connect with the bleeding disorders community. #BDC2026

0:10